<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621019</url>
  </required_header>
  <id_info>
    <org_study_id>BTL-785F_ABL</org_study_id>
    <nct_id>NCT04621019</nct_id>
  </id_info>
  <brief_title>BTL-785F Device for Non-invasive Lipolysis and Circumference Reduction of the Abdomen</brief_title>
  <official_title>Evaluation of the Safety and the Efficacy of the of BTL-785F Device for Non-invasive Lipolysis and Circumference Reduction of the Abdomen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTL Industries Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTL Industries Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical safety and the performance of the BTL-785F system&#xD;
      equipped with BTL-785-1 applicator for non-invasive lipolysis (breakdown of fat) of the&#xD;
      abdomen and reduction in circumference of the abdomen.&#xD;
&#xD;
      Safety measures will include documentation of adverse events (AE) during and after the&#xD;
      procedures.&#xD;
&#xD;
      Follow-ups visits at 1 month and 3 months after the final treatment will be held.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Statistically significant reduction of abdominal fat thickness determined with ultrasound</measure>
    <time_frame>5 months</time_frame>
    <description>To gather clinical evidence that BTL-785F system equipped with BTL-785-1 applicator is able to provide statistically significant reduction of at least 1,5 cm at the 3-months follow-up compared to baseline with a minimum response rate of 65% in both abdominal circumference and fat thickness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety of the BTL-785F device with BTL-785-1 applicator for non-invasive lipolysis and circumference reduction of the abdomen</measure>
    <time_frame>5 months</time_frame>
    <description>At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device.&#xD;
Safety measures will include documentation of adverse events (AE) during and after the procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the participants' satisfaction from the therapy measured via standard questionnaire</measure>
    <time_frame>5 months</time_frame>
    <description>Minimum 80% of treated subjects to report satisfaction (level satisfied and higher) with the therapy;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fat Burn</condition>
  <arm_group>
    <arm_group_label>Non-invasive lipolysis and circumference reduction of the abdomen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment administration phase consists of four (4) treatment visits, delivered at least 1 week apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BTL-785F</intervention_name>
    <description>Treatment with study device.</description>
    <arm_group_label>Non-invasive lipolysis and circumference reduction of the abdomen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects over 21 years of age seeking treatment for abdominal&#xD;
             circumference reduction&#xD;
&#xD;
          -  Subjects should be able understand the investigative nature of the treatment, the&#xD;
             possible benefits and side effects, and must sign the Informed Consent Form&#xD;
&#xD;
          -  Presence of clearly visible fat deposits in the abdominal area as deemed appropriate&#xD;
             by the Investigator (e.g. by pinch test or ultrasound fat thickness measurement)&#xD;
&#xD;
          -  Subjects willing and able to abstain from partaking in any treatments other than the&#xD;
             study procedure to promote body contouring and/or weight loss during study&#xD;
             participation.&#xD;
&#xD;
          -  No procedure for abdominal fat reduction (including cellulite treatment) in the last&#xD;
             six months.&#xD;
&#xD;
          -  Subjects willing and able to maintain his/her regular (pre-procedure) diet and&#xD;
             exercise regimen without effecting a significant change of weight in either direction&#xD;
             during study participation.&#xD;
&#xD;
          -  Willingness to comply with study instructions and to return to the clinic for required&#xD;
             visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bacterial or viral infection, acute inflammations&#xD;
&#xD;
          -  Impaired immune system&#xD;
&#xD;
          -  Isotretinoin use in the past 12 months&#xD;
&#xD;
          -  Skin related autoimmune diseases&#xD;
&#xD;
          -  Radiation therapy and/or chemotherapy&#xD;
&#xD;
          -  Poor healing and unhealed wounds in the treatment area&#xD;
&#xD;
          -  Metal implants&#xD;
&#xD;
          -  Permanent implant in the treated area&#xD;
&#xD;
          -  Pacemaker or internal defibrillator, or any other active electrical implant anywhere&#xD;
             in the body&#xD;
&#xD;
          -  Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or pre-malignant moles&#xD;
&#xD;
          -  History of any type of cancer&#xD;
&#xD;
          -  Active collagen diseases&#xD;
&#xD;
          -  Cardiovascular diseases (such as vascular diseases, peripheral arterial disease,&#xD;
             thrombophlebitis and thrombosis)&#xD;
&#xD;
          -  Pregnancy/nursing or IVF procedure&#xD;
&#xD;
          -  History of bleeding coagulopathies, use of anticoagulants&#xD;
&#xD;
          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, etc.&#xD;
&#xD;
          -  Any surgical procedure in the treatment area within the last three months or before&#xD;
             complete healing&#xD;
&#xD;
          -  Poorly controlled endocrine disorders, such as diabetes&#xD;
&#xD;
          -  Acute neuralgia and neuropathy&#xD;
&#xD;
          -  Kidney or liver failure&#xD;
&#xD;
          -  Sensitivity disorders in the treatment area&#xD;
&#xD;
          -  Varicose veins, pronounced edemas&#xD;
&#xD;
          -  Previous liposuction in the treatment area in the last six months&#xD;
&#xD;
          -  Unstable weight within the last 6 months (change in weight Â± 3%)&#xD;
&#xD;
          -  Previous body contouring or cellulite treatments in the abdominal area in the last six&#xD;
             months&#xD;
&#xD;
          -  Any other disease or condition (e.g. hernia) at the investigator discretion that may&#xD;
             pose risk to the patient or compromise the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Georgi Petkov</last_name>
    <phone>+359 32 622 252</phone>
    <email>petkov@btl.bg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ambulatory for Individual Practice for Specialized Outpatient Medical Care in Dermatology and Venereology Dr. Ivelina Yordanova-Vasileva</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <contact>
      <last_name>Ivelina Yordanova-Vasileva, MD</last_name>
      <phone>+359878 840912</phone>
    </contact>
    <investigator>
      <last_name>Ivelina Yordanova-Vasileva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Lekova Derm Ltd.</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <contact>
      <last_name>Desislava Lekova, MD</last_name>
      <phone>+359 87 787 5865</phone>
    </contact>
    <investigator>
      <last_name>Desislava Lekova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lipolysis</keyword>
  <keyword>circumference reduction</keyword>
  <keyword>non-invasive</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

